Search
Statistics
We have 222 registered usersThe newest registered user is raheelmemon
Our users have posted a total of 1140 messages in 613 subjects
If you are seeing this, you have attempted to link to the UpToDate widget but are experiencing a problem. Please visit UpToDate for more information.
FDA Drug Safety Communication: SSRI use during pregnancy
FORUM FOR PSYCHIATRY RESIDENTS :: Psychiatry :: Psychiatry-Neurology-Psychology discussion :: Psycho-Pharmacology
Page 1 of 1
FDA Drug Safety Communication: SSRI use during pregnancy
FDA Drug Safety Communication: Selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies
The Division of Drug Information (DDI) is CDER's focal point for public inquiries. We serve the public by providing information on human drug products and drug product regulation by FDA.
___________________________________________________________________________________________________________________________________________________
The U.S. Food and Drug Administration (FDA) is updating the public on the use of selective serotonin reuptake inhibitor (SSRI) antidepressants by women during pregnancy and the potential risk of a rare heart and lung condition known as persistent pulmonary hypertension of the newborn (PPHN). The initial Public Health Advisory in July 2006 on this potential risk was based on a single published study. Since then, there have been conflicting findings from new studies evaluating this potential risk, making it unclear whether use of SSRIs during pregnancy can cause PPHN.
At this time, FDA advises health care professionals not to alter their current clinical practice of treating depression during pregnancy. Healthcare professionals should report any adverse events involving SSRIs to the FDA MedWatch Program.
FDA has reviewed the additional new study results and has concluded that, given the conflicting results from different studies, it is premature to reach any conclusion about a possible link between SSRI use in pregnancy and PPHN. FDA will update the SSRI drug labels to reflect the new data and the conflicting results.
PPHN occurs when a newborn baby does not adapt to breathing outside the womb. Newborns with PPHN may require intensive care support including a mechanical ventilator to increase their oxygen level. If severe, PPHN can result in multiple organ damage, including brain damage, and even death.
For more information please visit: SSRI use during pregnancy
Similar topics
» FDA Drug Safety Communication: Serious CNS reactions possible when Linezolid given with certain psychiatric medications
» Standard SSRI Dosage
» Pediatric Depression- Which SSRI is Superior?
» Breast Cancer Recurrence Risk Related to Concurrent Use of SSRI Antidepressants and Tamoxifen
» MedSmart- Engage Your Patients in Medication Safety
» Standard SSRI Dosage
» Pediatric Depression- Which SSRI is Superior?
» Breast Cancer Recurrence Risk Related to Concurrent Use of SSRI Antidepressants and Tamoxifen
» MedSmart- Engage Your Patients in Medication Safety
FORUM FOR PSYCHIATRY RESIDENTS :: Psychiatry :: Psychiatry-Neurology-Psychology discussion :: Psycho-Pharmacology
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
Sat Sep 10, 2016 1:45 pm by Admin
» L-Methylfolate: Who Will benefit
Sat Sep 03, 2016 3:00 pm by Admin
» Vitamins & Supplements in Clinical Practice.
Sun Aug 21, 2016 12:27 pm by Admin
» Imaging Biomarkers for Outcomes in Mild TBI
Fri Jul 22, 2016 12:37 pm by Admin
» Q.5 Clozapine Neutopenia
Mon Jul 11, 2016 8:43 pm by Admin
» Treating Disorders!
Mon Jul 04, 2016 1:52 am by troymackys
» Cortical Abnormalities in Adults & Adolescents with MDD
Sun Jul 03, 2016 12:59 pm by Admin
» Efficacy of Antipsychotics in Pediatric Acute Mania
Wed Jun 22, 2016 8:46 pm by Admin
» Obsessive Compulsive Disorder in Adults: Which Treatment is Better?
Tue Jun 21, 2016 9:34 pm by Admin